Intellia Therapeutics (NASDAQ:NTLA) Lowered to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a sell rating in a research note released on Tuesday morning, Zacks.com reports.

According to Zacks, “Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia’s combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products. “

Several other research analysts have also recently weighed in on the stock. Raymond James raised shares of Intellia Therapeutics from a market perform rating to an outperform rating and set a $24.00 price target on the stock in a report on Friday, November 1st. Chardan Capital reissued a buy rating and issued a $57.50 price target on shares of Intellia Therapeutics in a report on Monday, February 10th. ValuEngine cut shares of Intellia Therapeutics from a buy rating to a hold rating in a report on Tuesday, November 5th. Finally, BidaskClub raised shares of Intellia Therapeutics from a sell rating to a hold rating in a report on Thursday, February 6th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The stock has an average rating of Hold and an average target price of $25.25.

Intellia Therapeutics stock opened at $13.86 on Tuesday. The stock has a market cap of $677.51 million, a P/E ratio of -7.04 and a beta of 2.82. The company has a quick ratio of 7.89, a current ratio of 7.89 and a debt-to-equity ratio of 0.05. Intellia Therapeutics has a twelve month low of $10.26 and a twelve month high of $19.00. The company’s 50-day moving average price is $14.27 and its two-hundred day moving average price is $14.54.

Institutional investors and hedge funds have recently made changes to their positions in the company. UBS Asset Management Americas Inc. acquired a new stake in shares of Intellia Therapeutics during the 2nd quarter worth approximately $299,000. Nuveen Asset Management LLC acquired a new stake in shares of Intellia Therapeutics during the 2nd quarter worth approximately $2,416,000. Royal Bank of Canada boosted its position in shares of Intellia Therapeutics by 277.9% during the 2nd quarter. Royal Bank of Canada now owns 133,723 shares of the company’s stock worth $2,189,000 after acquiring an additional 98,339 shares in the last quarter. Dupont Capital Management Corp acquired a new stake in shares of Intellia Therapeutics during the 3rd quarter worth approximately $321,000. Finally, Nikko Asset Management Americas Inc. boosted its position in shares of Intellia Therapeutics by 40.3% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 7,239,737 shares of the company’s stock worth $96,650,000 after acquiring an additional 2,078,639 shares in the last quarter. 90.10% of the stock is currently owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.

Further Reading: Derivative

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.